BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10683120)

  • 1. Rosiglitazone approved for treatment of type 2 diabetes.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1292, 1294. PubMed ID: 10683120
    [No Abstract]   [Full Text] [Related]  

  • 2. Anticipated US approval for rosiglitazone and pioglitazone.
    Diabetes Obes Metab; 1999 May; 1(3):181-2. PubMed ID: 11220298
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacologic therapy for type 2 diabetes mellitus.
    DeFronzo RA
    Ann Intern Med; 2000 Jul; 133(1):73-4. PubMed ID: 10877745
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
    Gorman C
    Time; 2000 Apr; 155(13):94. PubMed ID: 11009709
    [No Abstract]   [Full Text] [Related]  

  • 5. The long Avandia endgame.
    Mullard A
    Lancet; 2011 Jul; 378(9786):113. PubMed ID: 21748869
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA approves pioglitazone for diabetes.
    Miller JL
    Am J Health Syst Pharm; 1999 Sep; 56(17):1698. PubMed ID: 10512494
    [No Abstract]   [Full Text] [Related]  

  • 7. Rosiglitazone: a case of regulatory hubris.
    Nissen SE
    BMJ; 2013 Dec; 347():f7428. PubMed ID: 24335808
    [No Abstract]   [Full Text] [Related]  

  • 8. Thiazolidinediones: a comparative review of approved uses.
    Sood V; Colleran K; Burge MR
    Diabetes Technol Ther; 2000; 2(3):429-40. PubMed ID: 11467345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes.
    Cheng-Lai A; Levine A
    Heart Dis; 2000; 2(4):326-33. PubMed ID: 11728276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone.
    Goldstein BJ
    Int J Clin Pract; 2000 Jun; 54(5):333-7. PubMed ID: 10954962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From the Food and Drug Administration.
    Henney JE
    JAMA; 1999 Sep; 282(10):932. PubMed ID: 10485665
    [No Abstract]   [Full Text] [Related]  

  • 12. [First insulin sensitizer approved in Germany. Insulin resistance in type 2 diabetes can be treated].
    MMW Fortschr Med; 2000 Sep; 142(36):50. PubMed ID: 11021073
    [No Abstract]   [Full Text] [Related]  

  • 13. Warner Lambert/Sankyo diabetes drug nears market.
    Nat Biotechnol; 1997 Feb; 15(2):113. PubMed ID: 9035120
    [No Abstract]   [Full Text] [Related]  

  • 14. Rosiglitazone and type 2 diabetes mellitus.
    Bragg T
    Lancet; 2001 May; 357(9266):1451. PubMed ID: 11360960
    [No Abstract]   [Full Text] [Related]  

  • 15. Rosiglitazone for type 2 diabetes mellitus.
    Med Lett Drugs Ther; 1999 Aug; 41(1059):71-3. PubMed ID: 10603986
    [No Abstract]   [Full Text] [Related]  

  • 16. Rosiglitazone monotherapy and type 2 diabetes.
    Lawrence IG
    Diabet Med; 2001 Nov; 18 Suppl 4():6-8. PubMed ID: 11989215
    [No Abstract]   [Full Text] [Related]  

  • 17. [Type II diabetes mellitus. Rosiglitazone is effective against insulin resistance].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1999 Sep; 22(9):288-9. PubMed ID: 10577070
    [No Abstract]   [Full Text] [Related]  

  • 18. Rosiglitazone and the FDA.
    Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R
    N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586
    [No Abstract]   [Full Text] [Related]  

  • 19. Pioglitazone and rosiglitazone for diabetes.
    Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidance on rosiglitazone for type 2 diabetes mellitus.
    Matthews DR
    Lancet; 2001 Feb; 357(9254):481. PubMed ID: 11273100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.